M3 receptor Inhibitors
3 drugsAbout M3 receptor
The M3 receptor is a muscarinic acetylcholine receptor subtype and a GPCR involved in physiological processes like smooth muscle contraction and glandular secretion.
The M3 receptor is a drug target in respiratory conditions, though there is currently no genetic evidence linking it to specific diseases.
Three FDA-approved drugs, including STIOLTO RESPIMAT, TIOTROPIUM BROMIDE, and BEVESPI AEROSPHERE, target the M3 receptor; all are small molecules.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Bladder Cancer with only 1 trials.
Top M3 receptor Drugs
Three companies, Boehringer Ingelheim, Lupin, and AstraZeneca, have approved drugs targeting M3.
Limited number of players suggests moderate barriers to entry, but also a risk of me-too drugs.
M3 receptor Drug Modality Landscape
Modalities
Routes of Administration
M3 receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide differentiation and novel IP.
M3 receptor Clinical Trials 210 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 23 | 20 | 1 | 2 | 95% |
| Phase 2 | 52 | 43 | 7 | 2 | 86% |
| Phase 3 | 79 | 74 | 4 | 1 | 95% |
| Phase 4 | 56 | 46 | 9 | 1 | 84% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved M3 receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting M3 receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
M3 receptor Drug Approval Timeline (2012 - 2023)
The first drug was approved in 2015, and the most recent in 2023, spanning 9 years.
Recent approval suggests continued interest, but approaching saturation; new mechanisms may be needed.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 96 clinical trials targeting M3 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities